Reuters: Regulatory News: MannKind diabetes therapy succeeds in late-stage studies

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

50% off Print Subscription of USA Today Get the news delivered to your doorstep. Lock in the savings and receive USA Today for just $0.75 a day. From our sponsors

MannKind diabetes therapy succeeds in late-stage studies Aug 14th 2013, 10:24 Wed Aug 14, 2013 6:24am EDT Aug 14 (Reuters) - MannKind Corp said results of two late-stage studies showed that its experimental diabetes therapy was more effective than insulin and oral diabetes treatments. The therapy, called Afrezza, is designed to treat adult patients with Type 1 and Type 2 diabetes. It consists of a powder loaded into a cartridge and used as an inhaler. Results from the two studies included reduction in fasting blood glucose levels and lower incidences of hypoglycemia. MannKind said it expects to submit data from the trials to the U.S. Food and Drug Administration in the fourth quarter ending December.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions